ENTEROSGEL RESEARCH · PEER-REVIEWED · PUBLISHED

IS ENTEROSGEL CLINICALLY PROVEN?

Yes. ENTEROSGEL has been studied in randomised clinical trials in adults, children and people with IBS-D, and in laboratory studies, published in GUT, BMJ journals and Scientific Reports.

3
randomised clinical trials
440
adults in the RELIEVE IBS-D trial
28
UK trial sites
2024
The Lancet Gastroenterology & Hepatology: first-line option
Bacterial toxins illustration
Bacterial toxins
Excess bile acids illustration
Excess bile acids
Inflammatory molecules illustration
Inflammatory molecules
RESEARCHED · PUBLISHED · TRUSTED
Sold in Boots
RELIEVE IBS-D · 2022
Gastro & Hepatology · 2024
Adults & children
2025 study
GP conference
THE EVIDENCE

WHAT DO THE ENTEROSGEL STUDIES SHOW?

Three randomised trials and the laboratory science behind them, each with a link to the original paper.
IBS-D · RCT GUT · 2022

RELIEVE IBS-D

Double-blind, randomised, placebo-controlled trial in 440 adults with IBS-D at 28 UK sites. Chief Investigator: Prof Yan Yiannakou.

76%
reported adequate relief of IBS-D symptoms (open-label phase)
Relieved the global symptoms of IBS-D and improved quality of life.
Howell CA et al. Gut 2022;71:2430–2438 · doi:10.1136/gutjnl-2022-327293
Read in GUT ↗
Adults · RCT BMJ Open Gastroenterology · 2019

Acute diarrhoea in UK primary care

Randomised trial in 105 adults with acute diarrhoea in UK GP practices: ENTEROSGEL with rehydration versus rehydration alone. Investigator: Dr Preeti Pandya.

~12 h
sooner to the first normal stool (≈27 h vs 39 h)
72% had resolved by 36 hours, versus 57% with standard care. Well tolerated.
Howell CA et al. BMJ Open Gastroenterol 2019;6:e000287
Read in BMJ Open Gastro ↗
Children · RCT BMJ Paediatrics Open · 2025

Acute diarrhoea in young children

Randomised feasibility study in 50 children aged 6–59 months in The Gambia, led by Prof Stephen Allen. ENTEROSGEL was mixed straight into ORS.

≈½
the time to last watery stool (≈20 h vs 39 h)
Acceptable to families and well tolerated.
Radeh P, Allen S et al. BMJ Paediatr Open 2025;9:e003133
Read in BMJ Paediatrics Open ↗
Laboratory Scientific Reports · 2019

Selective adsorption

In vitro study of what the gel binds: bacterial toxins (E. coli endotoxin, Shigella and C. difficile toxins) and excess bile acids.

10×
lower binding of tested medicines than activated charcoal
Selective: binds harmful substances while largely sparing the medicines tested.
https://doi.org/10.1038/s41598-019-42176-z
Read in Scientific Reports ↗
LANDMARK STUDY · IBS-D

WHAT DID THE RELIEVE IBS-D TRIAL FIND?

The largest trial of an intestinal adsorbent in IBS-D. ENTEROSGEL relieved the global symptoms of IBS-D and improved quality of life, which is why it is now named a first-line option in The Lancet Gastroenterology & Hepatology (2024).

QUALITY OF LIFE IMPROVED IN:
😊 Satisfaction with life
↕ Everyday activities
🛡️ Body image
☁️ Less health worry
🍽️ Less food avoidance
💗 Social life & relationships
Prof Yan Yiannakou
“ENTEROSGEL significantly improves quality of life of my patients with diarrhoea and IBS.”
Prof Yan Yiannakou · Consultant Gastroenterologist · Chief Investigator, RELIEVE IBS-D
76%
reported adequate relief of IBS-D symptoms*
440
adults in a double-blind, placebo-controlled UK trial at 28 sites
2024
The Lancet Gastroenterology & Hepatology: proposed as a first-line option when diarrhoea and urgency dominate
*Open-label phase. Howell CA et al. Gut 2022;71:2430–2438 · Black CJ, Ford AC. Lancet Gastroenterol Hepatol 2024
🏆
AWARD-WINNING RESEARCH
Falk Foundation / Guts UK Medical Student Prize 2025
Imperial College London
LABORATORY RESEARCH · 2025

DOES ENTEROSGEL BIND INFLAMMATORY MOLECULES?

In a laboratory study at Imperial College London, ENTEROSGEL adsorbed key inflammatory molecules within 15 minutes under the reported conditions.

98.7%
IL-1β
95.8%
TNF-α
99.4%
MMP-9
Laboratory evidence does not by itself establish a clinical outcome. Kaur-Paneser S, Hanna L, Powell N, Carrington EV. Imperial College London, 2025.
Children playing outdoors
● NOW RECRUITING
ONGOING RESEARCH

WHAT IS ENTEROSGEL BEING STUDIED FOR NEXT?

ENTOPIC is a UK randomised, double-blind, placebo-controlled trial of ENTEROSGEL for functional abdominal pain disorders in children aged 3–18, assessing pain, gut symptoms and quality of life. These conditions affect more than 1 in 9 children worldwide.

ISRCTN16474818
QUICK ACCESS

WHERE CAN I READ THE ORIGINAL PUBLICATIONS?

Every link opens the publisher’s page
YEAR
JOURNAL
STUDY
DESIGN
SOURCE
2024
The Lancet Gastroenterology & Hepatology
Personalisation of therapy in IBS: ENTEROSGEL proposed as a first-line option for IBS-D
Review
2025
BMJ Paediatrics Open
ENTEROSGEL with ORS in children aged 6–59 months with acute diarrhoea
Randomised feasibility study
2025
Imperial College London
Adsorption of IL-1β, TNF-α and MMP-9 (Falk Foundation / Guts UK Medical Student Prize)
Laboratory
2022
GUT
RELIEVE IBS-D: ENTEROSGEL for IBS with diarrhoea
Double-blind RCT, 440 adults
2019
BMJ Open Gastroenterology
ENTEROSGEL for adults with acute diarrhoea in primary care
RCT, 105 adults
2019
Scientific Reports
Adsorption capacity for bacterial toxins, bile acids and medicines
Laboratory

Is ENTEROSGEL clinically proven?

Yes. ENTEROSGEL has been tested in three randomised clinical trials, in adults with IBS-D (440 patients, GUT 2022), adults with acute diarrhoea (BMJ Open Gastroenterology 2019) and young children with acute diarrhoea (BMJ Paediatrics Open 2025), and in laboratory studies published in Scientific Reports.

What did the RELIEVE IBS-D trial show?

In this double-blind, placebo-controlled trial of 440 adults at 28 UK sites, ENTEROSGEL relieved the global symptoms of IBS-D, including diarrhoea, urgency, bloating and abdominal pain, and improved quality of life. 76% reported adequate relief in the open-label phase.

Is ENTEROSGEL recommended by experts?

Yes. A 2024 review on personalising IBS treatment in The Lancet Gastroenterology & Hepatology named ENTEROSGEL as a first-line option for IBS-D where diarrhoea and urgency dominate.

How does ENTEROSGEL work, according to the research?

It is an oral intestinal adsorbent. Laboratory studies show it binds bacterial toxins, excess bile acids and inflammatory molecules, while binding far less of the medicines tested than activated charcoal. It is not absorbed into the blood.

Was ENTEROSGEL well tolerated in the trials?

Yes. It was well tolerated in the adult and children’s trials of acute diarrhoea and in the RELIEVE IBS-D trial.

Is more research under way?

Yes. ENTOPIC (ISRCTN16474818) is a UK randomised, double-blind, placebo-controlled trial of ENTEROSGEL in children with functional abdominal pain disorders.

FOR PATIENTS & FAMILIES

TRY THE PRODUCTS STUDIED

The 225 g tube and 4-week IBS-D course, travel sachets and Kids 0+: the same gel tested in the trials.

Shop ENTEROSGEL →
FOR HEALTHCARE PROFESSIONALS

BOOK A 15-MINUTE LEARNING SESSION

Research briefing, samples and patient leaflets for your practice or pharmacy.

Book a session →